July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy
Author Affiliations & Notes
  • Mitchell G Brigell
    Aerpio Pharmaceuticals, Cincinnati, Ohio, United States
  • Victor H Gonzalez
    Valley Retina Institute, Mcallen, Texas, United States
  • Darren J Bell
    Medical Center Ophthalmology Associates, San Antonio, Texas, United States
  • Arshad M. Khanani
    Sierra Eye Associates, Reno, Nevada, United States
  • Barbara Withers
    Aerpio Pharmaceuticals, Cincinnati, Ohio, United States
  • Laura Gambino
    Aerpio Pharmaceuticals, Cincinnati, Ohio, United States
  • Peter A Campochiaro
    Wilmer Eye Institute, Johns Hopkins University Medical Center, Baltimore, Maryland, United States
  • Kevin G Peters
    Aerpio Pharmaceuticals, Cincinnati, Ohio, United States
  • Steve Pakola
    Aerpio Pharmaceuticals, Cincinnati, Ohio, United States
  • Footnotes
    Commercial Relationships   Mitchell Brigell, Aerpio Pharmaceuticals (E); Victor Gonzalez, None; Darren Bell, None; Arshad Khanani, None; Barbara Withers, Aerpio Pharmaceuticals (E); Laura Gambino, Aerpio Pharmaceuticals (E); Peter Campochiaro, Aerpio Pharmaceuticals (F), Aerpio Pharmaceuticals (C); Kevin Peters, Aerpio Pharmaceuticals (E); Steve Pakola, Aerpio Pharmaceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1252. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mitchell G Brigell, Victor H Gonzalez, Darren J Bell, Arshad M. Khanani, Barbara Withers, Laura Gambino, Peter A Campochiaro, Kevin G Peters, Steve Pakola; Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1252.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tie2 dysfunction in the conventional outflow pathway has been implicated in glaucoma (Kim et al, JCI 2017; 127:3877-96). AKB-9778 is a small molecule inhibitor of VE-PTP, a critical negative regulator of Tie2, that is in clinical development for the treatment of diabetic retinopathy. The purpose of this exploratory analysis was to assess the effect of subcutaneous (SC) administration of AKB-9778, compared to placebo, on intraocular pressure (IOP) in patients with diabetic retinopathy.

Methods : Tie2 dysfunction in the conventional outflow pathway has been implicated in glaucoma (Kim et al, JCI 2017; 127:3877-96). AKB-9778 is a small molecule inhibitor of VE-PTP, a critical negative regulator of Tie2, that is in clinical development for the treatment of diabetic retinopathy. The purpose of this exploratory analysis was to assess the effect of subcutaneous (SC) administration of AKB-9778, compared to placebo, on intraocular pressure (IOP) in patients with diabetic retinopathy.

Results : Pretreatment baseline IOP assessment showed both the study eye and fellow eye of each treatment group to be normotensive and well balanced between treatment groups (Table 1). Both active AKB-9778 treatment arms achieved statistically significant reductions in IOP in both the study eye and the fellow eye compared to baseline, whereas there was no change in IOP in the placebo arm. In the subgroup of patients with baseline IOP > 16 mmHg, a greater IOP reduction was achieved.

Conclusions : SC administration of the Tie2 activator AKB-9778 was well tolerated and led to a statistically significant IOP reduction from baseline that was also statistically significantly greater than placebo. These results are consistent with preclinical and genetic evidence for the importance of Tie2 function on the conventional outflow pathway. These findings support evaluation of Tie2 activation by AKB-9778 as a potential approach for IOP reduction in patients with open angle glaucoma or ocular hypertension.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Table 1: Mean IOP and mean change from baseline IOP at Month-3 in study eye and fellow eye by treatment group

Table 1: Mean IOP and mean change from baseline IOP at Month-3 in study eye and fellow eye by treatment group

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×